GLP-1s for Pilots: FAA Medical Certification and the CACI Pathway

Before October 2023, the only weight-loss medication the FAA permitted was orlistat (Alli/Xenical), and even that required a 48-hour observation period. Every GLP-1 was effectively off-limits — forcing many pilots to choose between their medical and their metabolic health.

That changed with the FAA's introduction of the CACI — Weight Loss Management Worksheet. Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda, Victoza) are now approved under CACI — "Conditions an AME Can Issue." No Special Issuance authorization required. Your AME can issue your medical on the day of exam if all criteria are met.¹

Here's exactly what that looks like in practice.

The CACI framework

CACI stands for "Conditions AMEs Can Issue." It's the FAA's pathway for conditions that are well-managed, stable, and carry low risk of acute incapacitation in flight. Being on a CACI-approved medication means your Aviation Medical Examiner has the authority to issue your medical certificate directly, without routing the application through the Aerospace Medical Certification Division in Oklahoma City.²

The practical difference: days vs. months. A Special Issuance for a non-CACI condition can take 4–8 months to process. A CACI issuance happens in the exam room.

The specific requirements

To qualify under CACI for weight-loss indication, the pilot must meet all of the following:

• The condition being treated must be well controlled. For weight loss, this means documented progress — typically weight trend, BMI reduction, or body composition change.
• HbA1c must be under 6.5%. This is strict. An A1c at or above 6.5% places you in the diabetes pathway, which has different requirements.
• The pilot must be accompanied by a clinic note from the treating provider, dated within 90 days. The note must address: no symptoms or complications of diabetes, no impairing side effects from the medication, no hypoglycemic events.
• The AME reviews the FAA Weight Loss Management Worksheet to confirm eligibility.
• Single-medication use. If you're stacking a GLP-1 with a second weight-loss drug, CACI typically doesn't apply — Special Issuance may be required.
• Observation period after initiation. A minimum ground trial is required after starting the medication, to confirm no impairing side effects before flight.

The observation period — the most commonly missed requirement

Before you can fly on a newly started GLP-1 (or after a dose increase), you must complete a ground trial — no flying during the period. This is where pilots most often get tripped up.

The rationale: GLP-1 side effects like nausea, dizziness, and hypoglycemia in pre-diabetic patients could impair performance. The FAA wants to confirm you're stable before returning to the cockpit.

What's absolutely disqualifying

The diabetes pathway (if A1c is 6.5% or higher)

If your HbA1c crosses 6.5%, you're no longer in the weight-loss CACI pathway — you're in the Type 2 Diabetes pathway. This requires:

• A Diabetes Status Report completed by your treating physician.
• Documentation of stable glucose control, no episodes of severe hypoglycemia, no diabetic complications (retinopathy, neuropathy, nephropathy).
• Annual or more frequent submissions depending on class of medical.
• Potentially Special Issuance initially, with possible transition to CACI after a stability period.

The takeaway: if you're pre-diabetic and considering a GLP-1, starting before you cross into diabetic range keeps you in the easier CACI lane.

Off-label use for weight loss (Ozempic vs. Wegovy)

Semaglutide is marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management. Tirzepatide is marketed as Mounjaro (diabetes) and Zepbound (weight loss / OSA). The active ingredient is identical within each pair.

A common question: if Ozempic is prescribed off-label for weight loss, does the FAA require the Diabetes Status Report?

Based on guidance from the Aviation Medicine Advisory Service (AMAS) and reports from the pilot community, the FAA appears to treat the medication by active ingredient rather than strict brand name. A normal HbA1c with documentation that the medication is prescribed for weight loss (not diabetes) is generally interpreted correctly. Your AME's judgment ultimately controls — confirm before your exam.⁴

What about compounded semaglutide?

Many pilots have accessed GLP-1 therapy through compounding pharmacies during shortage periods and for cost reasons. The FAA's position on compounded semaglutide specifically isn't explicit, but general guidance treats compounded semaglutide as the same active ingredient as Ozempic/Wegovy. The key variable isn't the source — it's whether you meet the CACI criteria (controlled, documented, no side effects, HbA1c under threshold).

With FDA enforcement against compounded GLP-1s tightening in 2025–2026, many pilots are transitioning back to brand-name products to avoid regulatory ambiguity. If you're on compounded semaglutide and approaching a medical exam, consider whether the brand-name switch is cleaner.

The pilot-specific protocol

The muscle-loss concern for pilots

GLP-1 weight loss typically includes 25–40% lean mass loss without intervention.⁵ For pilots, this affects two things: G-tolerance (particularly for fighter and aerobatic pilots) and general stamina for long duty days. The countermeasures are the same as for any GLP-1 user:

• Protein: 1.6–2.0 g per kg of body weight daily.
• Resistance training 2–3x weekly, prioritizing compound movements.
• Creatine monohydrate 5 g/day.
• Adequate sleep — the circadian disruption of long-haul and red-eye flying compounds muscle loss signals.

Part 107, sport pilot, and BasicMed

The CACI framework applies to traditional 1st, 2nd, and 3rd class medicals. For pilots operating under:

• BasicMed: The medication management is a conversation with your physician rather than an FAA review. GLP-1s don't appear on the BasicMed CMEC disqualifying conditions list. Normal physician oversight applies.
• Sport pilot (self-declaration): You're required to self-certify fitness. If the medication and condition don't impair you, you can self-declare. Document your decision-making.
• Part 107 (drones): No medical required. Not applicable.

The bottom line for pilots

GLP-1s on your medical used to be a career question. Since October 2023, they're a CACI question — handled by your AME at exam if you meet straightforward criteria.

Keep your A1c under 6.5%. Complete the required ground trials. Carry a current 90-day clinic note. Document everything. Talk to your AME before starting, not after. Do those things, and you're flying on the medication with zero impact on your career trajectory.

A 45-year-old airline pilot with a BMI of 32 has more at risk from untreated obesity — cardiovascular events, OSA, type 2 diabetes progression — than from the straightforward paperwork of documenting a GLP-1 on the medical. The math favors treatment.